SEC Company Response from TALPHERA, INC. (TLPH) (CIK 0001427925) (TLPH) — Apr 22, 2020
TALPHERA, INC. (TLPH) (CIK 0001427925)
Date: April 22, 2020 · CIK: 0001427925 · Accession: 0001193125-20-114914
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-237584
Letter
VIA EDGAR Division of Corporation Finance Office of Manufacturing United States Securities and Exchange Commission Washington, D.C. 20549-3628 Attention: Irene Paik Re: Request for Effectiveness for AcelRx Pharmaceuticals, Inc. Registration Statement on Form S-4 (File No. 333-237584)
Dear Ms. Paik:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Act”), AcelRx Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 4:00 p.m. Eastern Time, on Friday, April 24, 2020, or as soon thereafter as practicable. In making this acceleration request, the Registrant acknowledges that it is aware of its responsibilities under the Act. The Registrant respectfully requests that you notify Rama Padmanabhan of Cooley LLP at (858) 550-6024 or, in her absence, Nicole P. van de Leuv of Cooley LLP at (858) 550-6150 of such effectiveness and that such effectiveness also be confirmed in writing to the addresses listed on the cover page of the Registration Statement.
If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Padmanabhan or Ms. van de Leuv at the telephone numbers above.
Very truly yours,
AcelRx Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP April 22, 2020 VIA EDGAR Division of Corporation Finance Office of Manufacturing United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Irene Paik Re: Request for Effectiveness for AcelRx Pharmaceuticals, Inc. Registration Statement on Form S-4 (File No. 333-237584) Dear Ms. Paik: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Act”), AcelRx Pharmaceuticals, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-referenced Registration Statement be accelerated to 4:00 p.m. Eastern Time, on Friday, April 24, 2020, or as soon thereafter as practicable. In making this acceleration request, the Registrant acknowledges that it is aware of its responsibilities under the Act. The Registrant respectfully requests that you notify Rama Padmanabhan of Cooley LLP at (858) 550-6024 or, in her absence, Nicole P. van de Leuv of Cooley LLP at (858) 550-6150 of such effectiveness and that such effectiveness also be confirmed in writing to the addresses listed on the cover page of the Registration Statement. If you have any questions or comments regarding the foregoing, please do not hesitate to contact Ms. Padmanabhan or Ms. van de Leuv at the telephone numbers above. Very truly yours, AcelRx Pharmaceuticals, Inc. By: /s/ Vincent J. Angotti Name: Vincent J. Angotti Title: Chief Executive Officer cc: Christopher D. Barnstable-Brown, Wilmer Cutler Pickering Hale and Dorr LLP Rama Padmanabhan, Cooley LLP AcelRx Pharmaceuticals, Inc • 351 Galveston Drive, Redwood City, CA 94063 • www.acelrx.com